Description

3H-1,2,3-Triazolo[4,5-D]Pyrimidin-7-Amine, n-[(4-Fluorophenyl)Methyl]-3-(Phenylmethyl)- (9Ci) is a specialized heterocyclic organic compound featuring a fused triazolopyrimidine core, which is a privileged scaffold in medicinal chemistry. This molecule matters as a high-value pharmaceutical intermediate or research chemical for developing novel therapeutic agents, particularly in kinase inhibitor programs. It is primarily needed by R&D and process chemistry teams within the pharmaceutical, biotechnology, and fine chemical industries. The compound, identified by CAS No. 606108-14-9, is supplied under stringent quality controls to ensure batch-to-batch consistency for critical synthesis workflows.

Application

This advanced chemical building block is designed for specialized research and development applications, including:

• Pharmaceutical Intermediate: Serving as a key precursor in the synthesis of potential drug candidates, especially kinase inhibitors and other targeted therapies.
• Medicinal Chemistry Research: Used in structure-activity relationship (SAR) studies and lead optimization due to its fused heterocyclic structure.
• Biochemical Probe Development: Potential use in creating tools for studying enzyme function and cellular signaling pathways.
• Fine Chemical Synthesis: Employed in multi-step organic syntheses to construct complex molecules for agrochemical or material science applications.
• Contract Research & Manufacturing (CRO/CMO): Supplied to organizations engaged in custom synthesis and process development for clients.
• Academic Research: Utilized in university and institutional labs for exploratory chemistry and novel methodology development.

Basic Information

Product Name	3H-1,2,3-Triazolo[4,5-D]Pyrimidin-7-Amine, n-[(4-Fluorophenyl)Methyl]-3-(Phenylmethyl)- (9Ci)
CAS No.	606108-14-9
Molecular Formula	C19H17FN6
Molecular Weight	348.38 g/mol
Synonyms	N-[(4-Fluorophenyl)methyl]-3-(phenylmethyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine; 3-Benzyl-N-[(4-fluorophenyl)methyl][1,2,3]triazolo[4,5-d]pyrimidin-7-amine; 3H-[1,2,3]Triazolo[4,5-d]pyrimidin-7-amine, N-[(4-fluorophenyl)methyl]-3-(phenylmethyl)-; 606108-14-9; N-[(4-Fluorobenzyl)]-3-benzyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-amine; Aurora Kinase Inhibitor I (related analog); Triazolopyrimidine derivative 606108-14-9; SCHEMBL15506227
EINECS	Contact for details

Quality Control

Every batch of our 3H-1,2,3-Triazolo[4,5-D]Pyrimidin-7-Amine derivative is produced and controlled under a cGMP-compliant quality management system, ensuring the highest standards for research and pharmaceutical use. Our products undergo rigorous quality testing, including advanced chromatographic and spectroscopic methods, to ensure compliance with stringent industry specifications. A comprehensive Certificate of Analysis (COA) detailing purity, identity, and impurity profiles is provided with each shipment to guarantee traceability and support your regulatory documentation.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry, and well-ventilated place at a controlled room temperature (typically 15-25°C). For long-term storage, consider storing under an inert atmosphere to maximize stability. Keep away from incompatible materials.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 97.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%
Heavy Metals	≤ 10 ppm
Single Unknown Impurity (HPLC)	≤ 0.5%
Total Impurities (HPLC)	≤ 3.0%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.